Therapeutic Area | MeSH |
---|---|
cardiovascular diseases | D002318 |
nutritional and metabolic diseases | D009750 |
Tradename | Proper name | Company | Number | Date | Products |
---|---|---|---|---|---|
Praluent | alirocumab | Regeneron Pharmaceuticals | N-125559 RX | 2015-07-24 | 2 products |
Brand Name | Status | Last Update |
---|---|---|
praluent | Biologic Licensing Application | 2021-05-05 |
Indication | Ontology | MeSH | ICD-10 |
---|---|---|---|
atherosclerosis | EFO_0003914 | D050197 | I25.1 |
hypercholesterolemia | HP_0003124 | D006937 | — |
Expiration | Code | ||
---|---|---|---|
alirocumab, Praluent, Regeneron Pharmaceuticals, Inc. | |||
2028-04-01 | Orphan excl. |
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
---|---|---|---|---|---|---|---|---|---|
Hypercholesterolemia | D006937 | HP_0003124 | — | 10 | 9 | 23 | 4 | 5 | 51 |
Dyslipidemias | D050171 | HP_0003119 | — | — | 1 | 1 | 3 | 4 | 9 |
Hyperlipoproteinemia type ii | D006938 | EFO_0004911 | E78.00 | — | 1 | 3 | 2 | 1 | 7 |
Atherosclerosis | D050197 | EFO_0003914 | I25.1 | 1 | — | — | 3 | 3 | 7 |
Cardiovascular diseases | D002318 | HP_0001626 | — | — | — | 2 | 1 | 2 | 5 |
Acute coronary syndrome | D054058 | EFO_0005672 | — | — | 1 | — | 1 | 3 | 5 |
Hyperlipidemias | D006949 | HP_0003077 | E78.5 | — | 1 | — | 2 | — | 3 |
Coronary artery disease | D003324 | — | I25.1 | — | — | — | 2 | 1 | 3 |
Myocardial infarction | D009203 | EFO_0000612 | I21 | — | — | — | 2 | — | 2 |
Angina pectoris | D000787 | EFO_0003913 | I20 | — | — | — | 1 | — | 1 |
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
---|---|---|---|---|---|---|---|---|---|
Sepsis | D018805 | HP_0100806 | A41.9 | 1 | 1 | 1 | — | — | 2 |
Atherosclerotic plaque | D058226 | HP_0031678 | I70 | — | — | 2 | — | — | 2 |
Septic shock | D012772 | — | A48.3 | — | 1 | 1 | — | — | 1 |
Peritoneal dialysis | D010530 | — | — | — | — | 1 | — | — | 1 |
Carotid artery diseases | D002340 | EFO_0003781 | — | — | — | 1 | — | — | 1 |
Renal dialysis | D006435 | EFO_0010690 | Z99.2 | — | — | 1 | — | — | 1 |
Type 2 diabetes mellitus | D003924 | EFO_0001360 | E11 | — | — | 1 | — | — | 1 |
Hiv infections | D015658 | EFO_0000764 | B20 | — | — | 1 | — | — | 1 |
Homozygous familial hypercholesterolemia | D000090542 | — | — | — | — | 1 | — | — | 1 |
Coronary circulation | D003326 | — | — | — | — | 1 | — | — | 1 |
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
---|---|---|---|---|---|---|---|---|---|
Intracranial arteriosclerosis | D002537 | EFO_1000860 | I67.2 | 1 | 1 | — | — | — | 2 |
Ischemic stroke | D000083242 | — | — | — | 1 | — | — | 1 | 2 |
St elevation myocardial infarction | D000072657 | — | — | — | 1 | — | — | — | 1 |
Nephrotic syndrome | D009404 | EFO_0004255 | N04 | — | 1 | — | — | — | 1 |
Non-small-cell lung carcinoma | D002289 | — | — | — | 1 | — | — | — | 1 |
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
---|---|---|---|---|---|---|---|---|---|
Healthy volunteers/patients | — | — | — | 3 | — | — | — | — | 3 |
Stroke | D020521 | EFO_0000712 | I63.9 | 1 | — | — | — | 1 | 2 |
Pharmacokinetics | D010599 | — | — | 1 | — | — | — | — | 1 |
Liver diseases | D008107 | HP_0002910 | K70-K77 | 1 | — | — | — | — | 1 |
Hemorrhage | D006470 | MP_0001914 | R58 | 1 | — | — | — | — | 1 |
Coronary disease | D003327 | — | — | 1 | — | — | — | — | 1 |
Pancreatic ductal carcinoma | D021441 | — | — | 1 | — | — | — | — | 1 |
Pancreatic neoplasms | D010190 | EFO_0003860 | C25 | 1 | — | — | — | — | 1 |
Neoplasms | D009369 | — | C80 | 1 | — | — | — | — | 1 |
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
---|---|---|---|---|---|---|---|---|---|
Genetic testing | D005820 | — | — | — | — | — | — | 1 | 1 |
Hyperlipoproteinemia type iii | D006952 | — | — | — | — | — | — | 1 | 1 |
Medication adherence | D055118 | EFO_0006344 | — | — | — | — | — | 1 | 1 |
Treatment adherence and compliance | D000074822 | — | — | — | — | — | — | 1 | 1 |
Patient compliance | D010349 | — | — | — | — | — | — | 1 | 1 |
Motivational interviewing | D062405 | — | — | — | — | — | — | 1 | 1 |
Compliance | D003187 | — | — | — | — | — | — | 1 | 1 |
Inflammation | D007249 | MP_0001845 | — | — | — | — | — | 1 | 1 |
Genetic polymorphism | D011110 | — | — | — | — | — | — | 1 | 1 |
Cognition | D003071 | EFO_0003925 | — | — | — | — | — | 1 | 1 |
Drug common name | Alirocumab |
INN | alirocumab |
Description | Alirocumab (human mab) |
Classification | Antibody |
Drug class | monoclonal antibodies |
Image (chem structure or protein) | |
Structure (InChI/SMILES or Protein Sequence) | — |
PDB | — |
CAS-ID | — |
RxCUI | — |
ChEMBL ID | CHEMBL2109540 |
ChEBI ID | — |
PubChem CID | — |
DrugBank | DB09302 |
UNII ID | PP0SHH6V16 (ChemIDplus, GSRS) |